Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Gay

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
JAMA Oncology|August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysisFrancesca Gay, Graham Jackson, Laura Rosiñol, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
JAMA Oncology|August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysisFrancesca Gay, Graham Jackson, Laura Rosiñol, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Pageof 18